Head and Neck Cancer, Radiotherapy; Complications
Conditions
Keywords
Nutritional support, Radiotherapy, Head and Neck Cancer, Complications
Brief summary
Nutritional deficiency and subsequent weight loss in patients with head and neck cancer is a common problem and a negative predictor of treatment outcomes and mortality, as well as quality of life. Nutritional support for patients is a prerequisite for the successful management of cancer patients. Sensory changes can be side effects of chemotherapy or ionizing radiation, which damages sensory receptors in the area of radiation, disrupts the function of the salivary glands, leading to hyposalivation and a decrease in taste. Individual choice of nutrition based on sensory sensations can significantly improve the quality of life of patients and ensure timely correction of their eating behavior.
Interventions
DIETARY_SUPPLEMENTOral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet
ONS with a cooling effect and Red Fruits taste. 3 bottles (х 200 ml) per day X 14 days (at severe mucositis period) in addition to a standard diet and other ONS without a sensor component and taste according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
DIETARY_SUPPLEMENTONS without a sensor component and taste + standard diet
Nutritional support + ONS without a sensor component and taste (cooling effect) in addition to a standard diet according to protein and energy requirements based on ESPEN guidelines (protein 1.5 g/kg/day and Energy -25 and 30 kcal/kg/day)
DIETARY_SUPPLEMENTStandard diet
Without appropriate nutritional support - not in accordance with current ESPEN guidelines (protein and Energy intake less than 1.5 g/kg/day and 25 and 30 kcal/kg/day). (Historical retrospective control).
Sponsors
National Medical Research Radiological Centre of the Ministry of Health of Russia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age\> 18 years * The presence of morphological verification of squamous cell carcinoma of the head and neck * No history of anticancer treatment * ECOG score 0 - 2 * Life expectancy is more than 3 months * Normal liver, kidney and bone marrow function * Absence of severe uncontrolled concomitant chronic diseases and acute diseases (including infectious diseases) * Absence of pregnancy, lactation * Initial compliance of patients (according to the consultation of a psychologist and questionnaires) with a signed informed consent
Exclusion criteria
* Simultaneous participation in another clinical trial * Failure to meet inclusion criteria * The patient's condition is ECOG ≥3, Karnovsky ≤40%. * Bleeding * Decay / Abscess in the area of tumor lesion * Pregnancy or breastfeeding * Refractory cachexia * Allergy or intolerance to any of the components of ONS
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life (QoL) | 1 year | QoL is evaluated and recorded according to questionnaire The Functional Assessment of Cancer Therapy - Fatigue (FACT-F) |
| Nutritional status | 1 year | Nutritional status is evaluated and recorded according to Nutritional Risk Screening (NRS) 2002 |
| Patient compliance | 1 year | The level of patient compliance is evaluated and recorded according to Morisky 8-Item Medication Adherence Questionnaire. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Unplanned breaks | during radiation treatment | Days of delayed treatment |
| Efficiency of chemoradiation therapy | 1 year | Degree of tumor resorption by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). |
| 1-year locoregional control | 1 year | 1-year locoregional control after chemoradiation therapy |
| Tolerance to chemoradiation therapy - dermatitis | 4 months | Dermatitis as adverse event of chemoradiation therapy is evaluated and recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 |
| 1-year relapse-free survival | 1 year | 1-year relapse-free survival is the percentage of people who have not had relaps one year after they started chemoradiation therapy |
| Dynamics of sensory changes | 1 year | Dynamics of sensory changes based on the adapted total soluble solids scale (TSS scale) |
| Dynamics of pain syndrome | 1 year | Dynamics of pain syndrome based on numerical rating scale (NRS scale) |
| 1-year overall survival | 1 year | 1-year overall survival is the percentage of people who are alive one year after they started chemoradiation therapy |
| Tolerance to chemoradiation therapy - mucositis | 4 months | Mucositis as adverse event of chemoradiation therapy is evaluated and recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 |
| Terms of treatment | during radiation treatment | Terms of treatment is recorded in total number of days from the first day of radiation treatment to the last one. |
Countries
Russia
Outcome results
None listed